An Open-Label Prospective, Non-Comparative Study to Explore the Tolerability, Safety and Effectiveness Upon Transition to Paliperidone ER in Patients With Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PERFECT
- Sponsors Janssen
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.